Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

Spirocyclic heterocyclic derivatives and methods of their use

Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases

The present invention is concerned with certain novel spiro substituted heterocyclic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenase. They may also be useful in the manufacture of pharmaceutical formulations for the treatment of lipoxygenase-mediated disorders.

Spiro derivatives as lipoxygenase inhibitors

The present invention provides a compound of formula (I) and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

Chroman derivatives as 5-hydroxytryptamine-6 ligands

The present invention relates to methods for inducing or promoting autophagy in a cell, the method comprising exposing to the cell an effective amount of a compound of formula I as described herein. The invention also relates to methods for treating or preventing diseases and disorders by administering to subjects in need thereof an effective amount of a compound of formula I, wherein the compound induces or promotes autophagy in at least one cell of the subject.

Method for inducing autophagy

The present invention relates to benzopyrans and benzoxepines of formula (I), wherein X, A, R1, R2 and (R)p have the meanings as given in claim 1, which can be used in the treatment of dislipidaemias, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes allowing the preparation of these compounds.

Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process

The present invention relates to benzopyran and benzoxepine derivatives of the general formula I, wherein X represents an oxygen atom, which can be used in the prevention or treatment of dyslipidemia, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes and intermediates allowing the preparation of these compounds.

Zeiller Jean Jaques

Papers

Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process

Benzopyran and benzoxepine derivatives, process of their preparation, their use and pharmaceutical preparations in which they are comprised